# Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment

> **NCT02581592** · PHASE1 · COMPLETED · sponsor: **Mylan Inc.** · enrollment: 16 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** TD-4208

## Key facts

- **NCT ID:** NCT02581592
- **Lead sponsor:** Mylan Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581592, "Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02581592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*